| Literature DB >> 35860666 |
Yinying Wang1, Rongsha Chen1, Zhongshan Yang2, Qian Wen3, Xia Cao1, Ninghui Zhao3, Jinyuan Yan1.
Abstract
Neurodegenerative diseases (NDs) are characterized by progressive degeneration and necrosis of neurons, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease and others. There are no existing therapies that correct the progression of these diseases, and current therapies provide merely symptomatic relief. The use of polysaccharides has received significant attention due to extensive biological activities and application prospects. Previous studies suggest that the polysaccharides as a candidate participate in neuronal protection and protect against NDs. In this review, we demonstrate that various polysaccharides mediate NDs, and share several common mechanisms characterized by autophagy, apoptosis, neuroinflammation, oxidative stress, mitochondrial dysfunction in PD and AD. Furthermore, this review reveals potential role of polysaccharides in vitro and in vivo models of NDs, and highlights the contributions of polysaccharides and prospects of their mechanism studies for the treatment of NDs. Finally, we suggest some remaining questions for the field and areas for new development.Entities:
Keywords: Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; mechanism; polysaccharides
Year: 2022 PMID: 35860666 PMCID: PMC9289469 DOI: 10.3389/fnagi.2022.917629
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.702
The different drug therapies available for the treatment of NDs.
| NDs | Medicine | Treatment mechanisms and disadvantages | References |
| AD | Cholinergic inhibitors (tacrine, donepezil, rivastigmine, and galantamine) | Increase the cholinergic levels in the brain by inhibiting the biological activity of AChE, and may cause adverse side effects (liver damage, nausea, vomiting, diarrhea, neuromuscular transmission and respiratory paralysis) |
|
| β1 amyloid (E2069, MK-8931) | Lower cerebral Aβ concentrations, may cause adverse side effects (hypomyelination, seizures, axon guidance defects, memory deficits, neurogenesis abnormalities) |
| |
| Antioxidant drugs (Monoamine oxidase inhibitors and melatonin) | Anti-inflammatory effects, cause adverse side effects (hepatotoxicity and hypertensive crisis, neuromuscular, autonomic, and mental status symptoms), and melatonin exerts its inhibitory effect on the generation of Aβ remains undefined | ||
| Calcium channel blockers (nilvadipine, nimodipine, and flunarizine) | Decrease calcium influx through the plasma membrane and impairment of synapse physiology, protect AD cells from Aβ oligomer production |
| |
| PD | Levodopa (L-DOPA), DOPA decarboxylase inhibitors | L-DOPA treatment is highly efficient, and is converted to DA and stored in the vesicles of presynaptic DA neurons, prolong use gives rise to motor abnormalities, including dyskinesia |
|
| Catechol-O-methyltransferase inhibitors | Inhibit of catechol-O-methyl transferase enzyme, and results in a higher levodopa concentration in the blood without peripheral degradation to 3-O-methyldopa, increase the bioavailability of L-DOPA, and may cause adverse side effects (liver toxicity, nausea, drowsiness, insomnia, dizziness, hallucination) |
| |
| Dopamine agonists | Act on either D1-like or D2-like dopamine receptors, and the multiple receptor subtypes present in the brain, produce dyskinesia identical to that of L-dopa |
| |
| Inhibitors of the enzyme monoamine oxidase type B | Degrade the neurotransmitter DA that is deficient in the nigro-striatal region in PD, and forms H2O2 and toxic aldehyde metabolites of DA, inhibit of DA degradation |
| |
| HD | Inhibitors of the vesicular monoamine transporter type 2 (Tetrabenazine and Deutetrabenazine) | Inhibit vesicular monoamine transporter (VMAT) type 2 and consequently decrease available dopamine in the synapse and interaction with postsynaptic dopamine receptors |
|
FIGURE 1The neuroprotective mechanisms of polysaccharides involved in neurodegenerative diseases (NDs). Drawn by Chen Shen, The Central laboratory of the Second Affiliated Hospital, Kunming Medical University.
Polysaccharides and their effects on PD.
| Experimental models | Source of polysaccharides | Effects | References |
| MPTP-induced mouse |
| Inhibit oxidative stress and increase DA levels |
|
| MPTP-induced mouse |
| Inhibit oxidative stress |
|
| 6-OHDA-induced mouse |
| Inhibit oxidative stress |
|
| H2O2-induced PC12 cells |
| Reduce oxidative stress |
|
| H2O2-induced PC12 cells |
| Attenuate intracellular ROS formation |
|
| MPP+ -induced PC-12 cells | Radix Ophiopogonis | Reverse oxidative stress and ER stress rise |
|
| Rotenone-induced SH-SY5Ycells | Low molecular weight Sulfated chitosan | Suppress mitochondrial dysfunction |
|
| Rotenone-induced Sprague-Dawley Rat | Focoidan | Enhance mitochondrial respiratory function |
|
| 6-OHDA-induced mice |
| Suppress neuroinflammation |
|
| MPP+-treated MES 23.5 cell membranes |
| prevent the production of microglia-derived proinflammatory |
|
| MPP+-induced |
| Inhibit apoptosis |
|
| 6-OHDA-induced PC12 cells |
| Decrease apoptosis |
|
| MPTP-induced mouse; |
| Attenuate autophagy |
|
| 6-OHDA-induced PC12 cells |
| Increase autophagy |
|
| MPTP-induced mouse | Polymannuronic acide | Modulate brain-gut-microbiota axis, increase gut microbial diversity and increase fecal SCFAs production. |
|
Polysaccharides and their effects on AD.
| Experimental models | Source of polysaccharides | Mechanism | References |
| APP/PSI transgenic mice |
| Restore synaptic plasticity |
|
| APP/PSI transgenic mice |
| Promote the recruitment of microglia to Aβ plaques |
|
| N2a/APP695 cells |
| Reduce Aβ peptide neurotoxicity |
|
| CHO/APPBACE1 and HEK293-APPsw cells |
| Enhance main enzymes (IDE and NEP) involved in Aβ degradation expression |
|
| transgenic |
| Reduce Aβ-induced toxicity |
|
| AAV2-hTau-infected C57/BL6 mice | Codonopsis pilosula | Attenuate Tau phosphorylation by increasing PP2A activity |
|
| Male Wistar rats |
| Decrease Tau phosphorylation by elevating PP2A and reducing APP, BACE1, GSK3 expression |
|
| 3xTg-AD mice | Mini-GAGR | Increase antioxidant enzymes decrease and p-Tau |
|
| 3xTg-AD mice | Midi-GAGR | Penetrate the BBB to reduce free reactive radicals and microglia cells |
|
| Male Sprague-Dawley rats |
| Regulate the balance of neurotransmitters |
|
| Aβ1-40 of AD mice | Porphyran | Increase ChAT activity and decreases AChE activity |
|
| Sprague-Dawley rats | Fucoidan | Inhibit cell apoptosis |
|
| Male KM mice |
| Decrease neuroinflammation |
|
| transgenic AD mice; |
| Enhance neurogenesis |
|
| C57BL/6J mice | lactulose and melibiose | Attenuate autophagy |
|
| C57BL/6J mice | Taxus chinensis var. mairei Cheng et L.K.Fu | Decrease oxidative stress |
|
| APP/PSI transgenic mice |
| Inhibit oxidative stress |
|
Polysaccharides and their effects on HD.
| Experimental models | Source of polysaccharides | Effects | References |
| HD-transgenic mice |
| Alleviate the cytotoxicity of mHtt |
|
|
|
| Reduce polyQ aggregation and alleviate neurotoxicity |
|
|
|
| Inhibit polyQ aggregation and alleviate the neurotoxicity |
|
|
|
| Reduce oxidative stress |
|
| transgenic |
| Reduce oxidative stress |
|
| 3-NP-induced SD rats | Ginseng saponins | Alleviate cytotoxicity of striatal neurons |
|